We estimate that the CEO of Prime Medicine, Inc. ($PRME), Allan Reine, M.D., received a compensation of $3,894,187 in 2025. This is a decrease of -18.74% from an estimated $4,623,802 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 23, 2026. Note that parsing errors may occur.
You can track $PRME on Quiver Quantitative's $PRME stock dashboard.
$PRME Stock Hedge Fund Activity
We have seen 108 institutional investors add shares of $PRME Stock stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 8,122,781 shares (-88.1%) from their portfolio in Q4 2025, for an estimated $28,186,050
- STATE STREET CORP added 3,798,884 shares (+293.0%) to their portfolio in Q4 2025, for an estimated $13,182,127
- FARALLON CAPITAL MANAGEMENT LLC removed 3,509,157 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $12,176,774
- BALYASNY ASSET MANAGEMENT L.P. added 3,076,489 shares (+6426.4%) to their portfolio in Q4 2025, for an estimated $10,675,416
- RA CAPITAL MANAGEMENT, L.P. removed 3,000,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $10,410,000
- BLACKROCK, INC. added 2,617,984 shares (+46.3%) to their portfolio in Q4 2025, for an estimated $9,084,404
- UBS GROUP AG added 2,135,810 shares (+700.8%) to their portfolio in Q4 2025, for an estimated $7,411,260
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRME Stock Analyst Ratings
Wall Street analysts have issued reports on $PRME in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $PRME Stock, check out Quiver Quantitative's $PRME forecast page.
$PRME Stock Price Targets
Multiple analysts have issued price targets for $PRME recently. We have seen 4 analysts offer price targets for $PRME in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Kostas Biliouris from Oppenheimer set a target price of $11.0 on 03/12/2026
- An analyst from LifeSci Capital set a target price of $6.0 on 12/23/2025
- Samantha Semenkow from Citigroup set a target price of $4.25 on 11/11/2025
- Geulah Livshits from Chardan Capital set a target price of $9.0 on 11/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
